MTOR and cancer: The enrichment of tumor-related pathways, including Akt pathway (NES=-2.04, p=0.004, FDR=0.068), Wnt pathway (NES=-1.95, p=0.008, FDR=0.087), p53 pathway (NES=1.95, p=0.012, FDR=0.243), mTOR signaling pathway (NES=-1.74, p=0.021, FDR=0.141), MAPK (NES=-1.89, p=0.014, FDR=0.107) pathway, Hedgehog signaling pathway (NES=-1.79, p=0.042, FDR=0.129) and ERKs pathway(NES=-2.03, p=0.008, FDR=0.068), suggested that abnormally expressed SLC22A12 may activate various cancer pathways that promote ccRCC occurrence or development.